public research university in Columbus, Ohio, United States
POPULARITY
Categories
1,516 episodes with ohio state
1,484 episodes with ohio state
1,253 episodes with ohio state
1,088 episodes with ohio state
1,406 episodes with ohio state
1,017 episodes with ohio state
800 episodes with ohio state
506 episodes with ohio state
910 episodes with ohio state
1,249 episodes with ohio state
674 episodes with ohio state
1,159 episodes with ohio state
735 episodes with ohio state
519 episodes with ohio state
697 episodes with ohio state
370 episodes with ohio state
401 episodes with ohio state
397 episodes with ohio state
338 episodes with ohio state
227 episodes with ohio state
421 episodes with ohio state
357 episodes with ohio state
346 episodes with ohio state
316 episodes with ohio state
285 episodes with ohio state
273 episodes with ohio state
389 episodes with ohio state
166 episodes with ohio state
239 episodes with ohio state
250 episodes with ohio state
227 episodes with ohio state
218 episodes with ohio state
238 episodes with ohio state
169 episodes with ohio state
171 episodes with ohio state
127 episodes with ohio state
265 episodes with ohio state
152 episodes with ohio state
284 episodes with ohio state
126 episodes with ohio state
115 episodes with ohio state
160 episodes with ohio state
131 episodes with ohio state
160 episodes with ohio state
191 episodes with ohio state
119 episodes with ohio state
359 episodes with ohio state
161 episodes with ohio state
111 episodes with ohio state
113 episodes with ohio state
117 episodes with ohio state
170 episodes with ohio state
106 episodes with ohio state
76 episodes with ohio state
Ohio State improved to 9-0 on the season following a 34-10 win over Purdue, making it an eight-straight game where it won by three-plus scores On this episode of Buckeye Talk, Stephen Means, Stefan Krajisnik and Andrew Gillis react to the win and discuss where they think OSU will be in the first College Football Playoff rankings. Thanks for listening to Buckeye Talk and sign up to get text messages from experts Stephen Means, Stefan Krajisnik and Andrew Gillis at 614-350-3315. Get the insider analysis, have your voice heard on the Buckeye Talk podcast and connect with the best Buckeye community out there. Learn more about your ad choices. Visit megaphone.fm/adchoices
Top-ranked Ohio State won at Purdue 34-10 on Saturday. Our postgame podcast, What We Learned Live, has reactions from host Dave Biddle, plus guests Heath Schneider, Mark Neal, Patrick Murphy and Steve Helwagen. What were the main takeaways from the game and what does it mean for the Buckeyes moving forward? We have that and much more for you on the show. To learn more about listener data and our privacy practices visit: https://www.audacyinc.com/privacy-policy Learn more about your ad choices. Visit https://podcastchoices.com/adchoices
Hosts Tom Orr and Tony Gerdeman preview the Ohio State - Purdue game and discuss the potential impact facing an Ohio State offensive line that could be down two key figures this week.
The Ohio State Buckeyes will take on Purdue on Saturday afternoon in Ross-Ade Stadium, and the Boilermakers will likely take the same approach as many OSU opponents have this season: take away star WR Jeremiah Smith and make someone else beat them. So how will Ryan Day's program respond? In this special bonus episode of the Buckeyes TomOrrow Morning podcast, you'll hear directly from Day and QB Julian Sayin about that, plus DT Kayden McDonald discusses his change in approach this year, and TE Max Klare talks about returning to the place where he played his first two seasons of college football, and where his younger brother is still on the Boilermaker football team.
Ohio State men’s basketball beat reporter Adam recaps the 94-68 victory over Purdue Fort Wayne on the latest episode of the BuckeyeXtra Basketball podcast. During this edition, we break down key takeaways from this matchup and talk about an in-game visit from the Podfather.
On this Friday Buckeye Talk, Stephen Means, Stefan Krajisnik and Andrew Gillis break down Ohio State's game against Purdue, and make their picks. Thanks for listening to Buckeye Talk and sign up to get text messages from experts Stephen Means, Stefan Krajisnik and Andrew Gillis at 614-350-3315. Get the insider analysis, have your voice heard on the Buckeye Talk podcast and connect with the best Buckeye community out there. Learn more about your ad choices. Visit megaphone.fm/adchoices
In this solo episode of The Gametime Guru Podcast, I'm sharing two stories that hit close to home—one from the sideline and one from the broader world of college sports. How I Learned (Again) That I Belong I relive one of my final club basketball games coaching in California—when my undersized team went toe-to-toe with a junior college squad and found a way to win. It's a raw look at belief, resilience, and learning how to win again after a stretch of setbacks. If you've ever questioned whether you belong—at work, in sport, or in life—this one's for you. The NIL Era: Opportunity & Uncertainty I break down the current state of Name, Image & Likeness (NIL) in college sports: How NIL is reshaping recruiting and roster retention Why powerhouse programs (think Ohio State) and mid-majors (like Boise State) face different realities The rise of donor fatigue and what it means for long-term sustainability Why NIL can be a double-edged sword—creating new opportunities for JUCO and DII athletes while adding pressure elsewhere Practical ideas for athletes (yes, even JUCO players) to build a brand—like starting a podcast and owning your story What you'll take away: How to rebuild confidence after a string of losses Why culture and standards help you "flip the switch" back to winning Actionable ways athletes and coaches can adapt in the NIL era If you're a coach, parent, athlete, or sports fan who believes games teach life, you'll feel right at home here. After nine years of conversations with athletes and coaches from 183 countries and all 50 states, I'm more convinced than ever: when you put in the work, you belong. If this episode resonates, follow the show and leave a 5-star review on Apple Podcasts—it helps the mission and keeps the conversations coming. Thanks for listening and for being part of the Gametime Guru community.
(00:00) - Charlie Marlow in the building!! Love that Chuck! Charlie updates us on what he's up to. Chuck learns us about a possible lawsuit with Michael Jordan and NASCAR. Charlie gives his take on Ohio State. (24:00) - SWV. Chuck misses seeing all the fellas. Story time. Jeff Fischer-era Rams trips. The Kevin Demoff “Professional Liar” super. (41:00) Tom's Diner. SEC Pick ‘Em with Charlie. See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.
Ohio State vs. Purdue: Game Preview & Predictions | Buckeye Weekly PodcastJoin Tony Gerdeman and Tom Orr on the Buckeye Weekly Podcast as they preview Ohio State's upcoming road game against Purdue. They discuss key matchups, player performances, and what the Buckeyes need to do to secure a win against a historically challenging opponent. Get insights on Purdue's strengths, weaknesses, and how the Ohio State offense can take advantage of the Boilermakers' defense. Don't miss the in-depth analysis and score predictions for this crucial Big Ten matchup!00:00 Introduction and Upcoming Road Trip00:48 Ohio State's History at Purdue02:53 Purdue's Current Season and Challenges04:13 Purdue's Offensive Strategy06:45 Ohio State's Defensive Strengths15:07 Purdue's Defensive Struggles22:00 Special Teams and Predictions28:53 Final Thoughts and Sign Off
Mason Wilhelm, a 2026 offensive line prospect out of St. Edward's High School in northeast Ohio, committed to play college football for the Ohio Stte Buckeyes.Wilhelm is the son of former OSU all-American linebacker Matt Wilhelm, and was previously committed to Bill Belichick and the North Carolina Tar Heels.Tony Gerdeman of BuckeyeHuddle.com joins host Tom Orr for this special breaking news episode of the Buckeyes TomOrrow Morning podcast.
Join our resident College Football connoisseur Scott Bogman as he brings you his favorite bets and props for Week 11 of the 2025 college football season! Timestamps: (May be off due to ads) Intro - 0:00:00Join our Discord community at bettingpros.com/chat - 0:00:15Week 10 Bets Recap - 0:00:47Week 11 Picks - 0:05:12Penn State Under 16.5 Team Total vs. Indiana - 0:05:18Mississippi State (+5.5) 1st Half vs. Georgia - 0:06:15Texas A&M @ Missouri Over 48.5 - 0:06:59Auburn Team Total Under 19.5 @ Vanderbilt - 0:08:05Florida (-3.5) @ Kentucky - 0:08:56Ohio State @ Purdue Under 48.5 | Purdue Team Total Under 8.5 vs. Ohio State - 0:09:51Virginia (-6.5) vs. Wake Forest - 0:11:13WVU (-6) vs. Colorado - 0:11:59Download the BettingPros App - 0:12:24Week 11 Props - 0:13:08TD Calls - 0:13:11WVU RB Diore Hubbard vs. Colorado - 0:13:13Florida RB Jaden Baugh @ Kentucky - 0:13:24Missouri RB Ahmad Hardy vs. Texas A&M - 0:13:39Ohio State WR Jeremiah Smith @ Purdue - 0:13:57UConn WR Skyler Bell vs. Duke - 0:14:09Yardage & Pass TD Props - 0:14:22WVU QB Scotty Fox Over 0.5 Passing TDs vs. Colorado - 0:14:25Maryland QB Malik Washington Over 1.5 Passing TDs @ Rutgers - 0:14:34Auburn QB Ashton Daniels Over 0.5 INTs @ Vanderbilt - 0:14:52LSU RB Harlem Berry Over 45.4 Rush+Rec Yds @ Alabama - 0:15:04TCU WR Eric McCalister Over 80.5 Rec Yds vs. Iowa State - 0:15:55Hard Rock Bet of the Week: Washington (-11.5) @ Wisconsin - 0:16:12Hard Rock Bet - 0:18:22Reviewing Week 11's Best Bets - 0:19:50 Helpful Links: Hard Rock Bet - All lines provided by Hard Rock Bet. Sign up for Hard Rock Bet and make a $5 bet and you'll get $150 in bonus bets if you win. Head over to Hard Rock Bet, sign up and make your first deposit today. Payable in bonus bet(s). Not a cash offer. Offered by the Seminole Tribe of Florida in FL. Offered by Seminole Hard Rock Digital, LLC, in all other states. Must be 21+ and physically present in AZ, CO, FL, IL, IN, NJ, OH, TN or VA to play. Terms and conditions apply. Concerned about gambling? In FL, call 1-888-ADMIT-IT. In IN, if you or someone you know has a gambling problem and wants help, call 1-800-9-WITH-IT. GAMBLING PROBLEM? CALL 1-800-GAMBLER (AZ, CO, IL, NJ, OH, TN, VA). BettingPros App - Make winning bets with advice and picks from top sports betting experts. The BettingPros app puts consensus and expert-driven sports betting advice at your fingertips to help you pinpoint the best odds and make winning bets. Download it today on the App Store or Google Play.BettingPros Deposit Offer – Score six months of BettingPros Premium for FREE! Just make a deposit and place your wager at a partner sportsbook. Premium gives you access to Sharp AI, our Betting Systems, the Prop Bet Cheat Sheet, and the Same Game Parlay Builder – all the tools you need to bet smarter. Claim your upgrade now at bettingpros.com/premium BettingPros Discord - Looking to up your game in sports betting? Join our exclusive sports betting Discord community at bettingpros.com/chat! Not only can you connect with expert handicappers who provide free picks for NBA, NFL, MLB, NHL, player props, live betting, and more, but now you can also participate in our weekly community picks. Cast your vote, see how your picks stack up against the experts, and track your success!See omnystudio.com/listener for privacy information.
Become a supporter of this podcast: https://www.spreaker.com/podcast/the-buckeye-scoop-podcast--4429642/support.
Become a supporter of this podcast: https://www.spreaker.com/podcast/the-buckeye-scoop-podcast--4429642/support.
Become a supporter of this podcast: https://www.spreaker.com/podcast/the-buckeye-scoop-podcast--4429642/support.
Become a supporter of this podcast: https://www.spreaker.com/podcast/the-buckeye-scoop-podcast--4429642/support.
Become a supporter of this podcast: https://www.spreaker.com/podcast/the-buckeye-scoop-podcast--4429642/support.
Become a supporter of this podcast: https://www.spreaker.com/podcast/the-buckeye-scoop-podcast--4429642/support.
Become a supporter of this podcast: https://www.spreaker.com/podcast/the-buckeye-scoop-podcast--4429642/support.
Become a supporter of this podcast: https://www.spreaker.com/podcast/the-buckeye-scoop-podcast--4429642/support.
Become a supporter of this podcast: https://www.spreaker.com/podcast/the-buckeye-scoop-podcast--4429642/support.
Happy Football Friday Edition of the Program!! Ohio State doesn't do it often but they are playing Purdue this week and the March to Michigan is officially on. We break down the matchup on both sides of the ball. We'll also hear what Coach Day and QB1 have to say about this one. Paul Depodesta is moving from Cleveland to Colorado and TNF was gross. Luke Fickel and Wisconsin have pledged themselves to each other and there are some CFP Eliminators this weekend. Tim May, Doug Lesmerises, What's Up, Learned and Earned, Thing or Not a Thing, Know the Scores and 3 Things to a Buckeye Victory
This date in history, Lee Sterling gives us his picks for the weekend, Quick Hitters: Brent Key loves Ga Tech & best CFB games this weekend, which Ohio State head coach was the most important between Jim Tressel, Urban Meyer and Ryan Day and we closed out the week as always with AJ Hawk.
Become a supporter of this podcast: https://www.spreaker.com/podcast/the-buckeye-scoop-podcast--4429642/support.
Become a supporter of this podcast: https://www.spreaker.com/podcast/the-buckeye-scoop-podcast--4429642/support.
Become a supporter of this podcast: https://www.spreaker.com/podcast/the-buckeye-scoop-podcast--4429642/support.
Become a supporter of this podcast: https://www.spreaker.com/podcast/the-buckeye-scoop-podcast--4429642/support.
Become a supporter of this podcast: https://www.spreaker.com/podcast/the-buckeye-scoop-podcast--4429642/support.
Become a supporter of this podcast: https://www.spreaker.com/podcast/the-buckeye-scoop-podcast--4429642/support.
Become a supporter of this podcast: https://www.spreaker.com/podcast/the-buckeye-scoop-podcast--4429642/support.
Become a supporter of this podcast: https://www.spreaker.com/podcast/the-buckeye-scoop-podcast--4429642/support.
Become a supporter of this podcast: https://www.spreaker.com/podcast/the-buckeye-scoop-podcast--4429642/support.
Senior NFL Reporter for TheMMQB.com Albert Breer joins the guys to dive into the various impacts of the NFL trade deadline and assess the future of Kyler Murray. Is it time to pump the brakes on the Colts being legit threats in the AFC?See omnystudio.com/listener for privacy information.
Upheaval has taken root at several college football programs. Not Ohio State. What does that mean? It means your Buckeyes are here to deal with upheaval effects - specifically recruits committed elsewhere that now have a potentially new take on their future. It's spatula season, 'Nutters! It came early this year based on all the coaching tomfoolery but hey, who are we to complain? Garrick Hodge and Mark Porter are here to flip it up. Who are the targets and what are the chances they tumble into Ohio State's recruiting class? We dive deep. We also hit the film room to break down Ohio State's victory over Penn State and try and put in perspective the voluminous and seemingly unprecedented level of praise heaped on the good guys these days. Spend 5ish with us this a.m., 'Nutters! To learn more about listener data and our privacy practices visit: https://www.audacyinc.com/privacy-policy Learn more about your ad choices. Visit https://podcastchoices.com/adchoices
Czabe welcomes on Mr. X to talk about why the faves can go 10-2 two weeks ago, and then the dogs go 9-5 the next week for no damn reason. If only we knew how and why. NFL refs are putting the screws to taunting penalties this year, and nobody likes it. Apparently nobody holds against Ohio State. Like, nobody. Are owner press conferences mid-season ever a good thing (no!) so why do some people like Jerrah do 'em? To "stir shit up" as he says. The college football "eye test" season is in, and Czabe explains why it's total bullshit. Plus, where you are ranked right now, actually DOES matter. Also the boys are on a roll with their TNF picks, so let's go 2-0 again this week! MORE....Our Sponsors:* Check out CBDfx and use my code CZABE for a great deal: https://cbdfx.com* Check out Hims: https://hims.com/CZABE* Check out Indeed: https://indeed.com/CZABE* Check out Infinite Epigenetics: https://infiniteepigenetics.com/CZABE* Check out Uncommon Goods: https://uncommongoods.com/czabeAdvertising Inquiries: https://redcircle.com/brandsPrivacy & Opt-Out: https://redcircle.com/privacy
Welcome to the Buckeye Talk Live Show. A weekly podcast brought to you live at noon every Wednesday for the 2025 season as Ohio State hopes to repeat as national champions. Every week, we'll discuss the program from a big picture perspective. This week, we discuss the Heisman Trophy and what our ballot would look like if the season ended today. Thanks for listening to Buckeye Talk and sign up to get text messages from experts Stephen Means, Stefan Krajisnik and Andrew Gillis at 614-350-3315. Get the insider analysis, have your voice heard on the Buckeye Talk podcast and connect with the best Buckeye community out there. Learn more about your ad choices. Visit megaphone.fm/adchoices
Nick Kostos & Femi Abebefe are LIVE! The guys talk all things NFL Week 10 and break down the latest line movement for this weekend's games. Plus, Nick reacts to the College Football Playoff rankings and breaks down why he thinks Ohio State is going to win another National Title. Plus, Brian Baldinger and Danny Parkins join the show!
In this episode of the Podcast of Champions hosts Ryan Abraham and David Woods talk about week ten in the Big Ten that included No. 1 Ohio State tearing the heart out of Penn State, leaving the Nittany Lions winless in conference play heading into November. The No. 19 ranked Trojans didn't play a clean game, but it was clean enough to take down Nebraska in Lincoln. The Huskers not only lost the game, but lost starting quarterback Dylan Raiola for the remainder of the season. Curt Cignetti continues his killing spree, obliterating Maryland before Indiana's debut at No. 2 in the first College Football Playoff rankings. Looking ahead to week 11, the guys preview and pick against the spread for all of the Big Ten games including the marquee game of the weekend with No. 9 Oregon at No. 20 Iowa. The guys also discuss those initial CFP rankings and discuss UCLA suing the Rose Bowl trying to get out of its contract to play there. As always, they wrap up the podcast by answering listener email and live chat questions. For the video simulcasts of our POC please subscribe to your YouTube channel! Please follow, give the POC a five-star rating and post a review on Apple Podcasts and Spotify! You can bet all of the Big Ten games over at MyBookie! To learn more about listener data and our privacy practices visit: https://www.audacyinc.com/privacy-policy Learn more about your ad choices. Visit https://podcastchoices.com/adchoices
In this breaking news episode of the Buckeye Weekly Podcast, hosts Tony Gerdeman and Tom Orr discuss the flip of Florida State cornerback commit Jay Timmons. The Buckeyes flipped an FSU legacy and Top 30 player in the nation. What kind of prospect is the Ohio State defense getting? The fellas discuss all of this and more.
Buckeye Weekly Podcast: Bold Predictions for Ohio State vs. PurdueIn this episode of the Buckeye Weekly Podcast, hosts Tony Gerdeman and Tom Orr share their bold predictions for the upcoming game between Ohio State and Purdue. The duo revisits last week's predictions, discussing accuracy and missed opportunities. They debate potential outcomes for the Ohio State defense and offense, including standout performances, key players' milestones, and specific yardage metrics. The episode concludes with their boldest predictions and a fun bonus round. Tune in to see who might come out on top this week!00:00 Introduction and Banter00:27 Revisiting Last Week's Predictions02:28 Bold Predictions for This Week03:52 Debating Max Klare's Touchdown07:18 More Bold Predictions and Justifications10:44 Defensive Touchdown Predictions13:59 Three Ohio State Scoring Drives16:40 Defensive Struggles and Bold Predictions17:25 Impact Players: Jackson and Curry17:59 Ohio State's Defensive Line and Linebackers19:59 Yards Per Play: Ohio State vs. Purdue23:59 Wide Receiver Predictions32:40 Running Back Challenges35:25 Final Thoughts and Bonus Predictions
Ohio State defensive coordinator Matt Patricia is running the nation's top defense for the nation's No. 1 team, but he's not resting on his laurels. Instead, Patricia is mixing in a number of different looks to keep opponents off-balance, and keep the Buckeyes' defense dominant.In this episode of Ross Fulton Analysis, Ross breaks down some of the different looks the Buckeyes showed in their 38-14 win over Penn State, and discusses a couple of things the Nittany Lions were able to do successfully, and how Patricia countered those later in the game.
In this must-listen episode of Hardcore Penn State Football, we bring the heat with special guest Landon Tengwall, the former Nittany Lions offensive lineman turned analyst and host of The Landon Tengwall Show, joining us for insider breakdowns and unfiltered takes on the program! We kick off with an exclusive interview with Landon—understanding what's going on with the current Penn State Football team. What improvements they can make at this point in the season? Can they get to a bowl game? We then talk about the Penn State Coaching Search and who Landon would like to see get the Penn State Head Coaching Job. Then, a raw dissection of what went wrong in the 38-14 thrashing by Ohio State and throughout this disappointing 3-5 campaign so far—turnovers, defensive lapses, coaching decisions, and how the Lions can salvage the year. Shifting to the future, our detailed preview of the upcoming clash against Indiana on November 8th at Beaver Stadium: Breaking down the #,2 Indiana Hoosiers, their high-powered offense, key matchups like containing their explosive WRS, and how Penn State's defense can step up at home. Next, our bold predictions for Penn State vs. Indiana—will the Nittany Lions snap their skid and get back to .500, or will IU keep rolling in the Big Ten? We cover scores, X-factors, and upset potential. Join Cory Lestochi and guest Landon Tengwall for candid convos, expert insights, and no-BS analysis. Subscribe now for more Penn State deep dives, like if you're ready for a rebound win, and drop your predictions in the comments! Visit rhettcoblentz.com for your graphic design needs! #WeAre #PennStateFootball #nittanylions WEEK 11 PICK'EM: https://forms.gle/UT44r58eJfDQoFJw5
The Prophets react to the first College Football Playoff rankings — how big is the gap between Ohio State and the rest of the field? Then, the guys dive into a wild NFL Trade Deadline where the Jets set off a New York firesale. Did the Cowboys just save their season by landing Quinnen Williams and Luke Wilson? And was the Colts' move to give up two first-rounders for Sauce Gardner a sign of desperation or a win-now statement? Lastly, the crew turns to the NBA as the Ja Morant situation in Memphis continues to spiral. Can he actually be traded — and which team would even want him?
Charlie Marlow discusses Eli Drinkwitz' coaching future, the Ohio State vs Penn State game and his thoughts on the World Series.#collegefootball #mizzou #elidrinkwitzBrought to you by!: https://www.triadbanking.com/Stay in beautiful Innsbrook, MO!: https://innsbrookvacations.com/vrp/unit/600_Whitetail_Waters-159-15
Ohio State is headed to Purdue, and thankful it's not at night. Hopefully all goes well this time. https://www.TheSloopCast.comArtist: Defiance, Ohio Song: Condition 11:11Link: https://www.youtube.com/watch?v=Q-cscyzIIpM
Scott Rizzuto, Anthony Stalter, and Tim McKernan return to The Spread Zone off a 6–3 week with bold energy, spicy locks, and an actual moment of agreement. Rizz finally puts together a clean card, Stalter recovers from NFL trauma, and Tim lets the AI pick his winners. This week's slate includes Mizzou -5.5 vs. Florida, Mississippi State (yes, again), Texas Tech -7 in a playoff pipe dream, and a heated group discussion around Ohio State laying 20.5. The NFL card gets weird with Bears takes, Seahawks love, and a full fade of the Giants, plus some mild panic about Falcons futures. FanDuel Locks of the Week are in—and yes, they're feeling dangerously confident.The Spread Zone is presented by FanDuel Sportsbook.*LEGAL DISCLAIMER*We provide information about sports betting for entertainment purposes only. Please confirm gambling regulations in your state of residence. To participate in sports gaming, you must be 21 years of age or older and be physically present in a state where sports betting is legal. If you or someone you know has a sports betting or gambling problem, please call 1-800-GAMBLER or visit www.ncpgambling.org for more information and further assistance.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.
Friday games (00:50): Houston at UCF, Northwestern at USC, Tulane at MemphisNoon games (3:25): BYU at Texas Tech, Georgia at Mississippi State, Indiana at Penn State, Southern Miss at Arkansas State, Ohio State at PurdueAfternoon games (12:31): Oregon at Iowa, Texas A&M at MissouriNight games (18:45): Wake Forest at Virginia, Cal at Louisville, Navy at Notre Dame, LSU at AlabamaPredictions (23:48): Southern Miss at Arkansas State, Georgia at Mississippi State, Wake Forest at Virginia, Cal at Louisville, Navy at Notre Dame, Tulane at Memphis, LSU at Alabama, Texas A&M at Missouri, Oregon at Iowa, BYU at Texas Tech
Dr. Monty Pal and Dr. Pauline Funchain discuss the latest efforts to diagnose, prevent, and treat the series of immune-related adverse events that have emerged in the era of immunotherapy. TRANSCRIPT Dr. Monty Pal: Hello, and welcome to the ASCO Daily News Podcast. I am Monty Pal, a medical oncologist, professor and vice chair of medical oncology at the City of Hope Comprehensive Cancer Center in Los Angeles, California. Now, it is probably no surprise to this audience that immunotherapy has transformed the treatment landscape for multiple cancer types. It remains a pillar of modern oncology. Having said that, I think we have all been baffled by certain toxicities that we run into in the clinic. Today, I am delighted to be joined by Dr Pauline Funchain to discuss some of the checkpoint inhibitor toxicities that people struggle with most. And we will also touch on some side effects of immunotherapy beyond checkpoint inhibitors: CAR-T cells, bispecifics, so on and so forth. Dr Funchain is a dear friend, and she is an associate professor and associate director of cancer research training and education at the Stanford Cancer Institute. She is co-director of the Immunotherapy Toxicity Program and the Skin Cancer Genomics Program at Stanford, where she also serves as associate program director of hematology and oncology fellowship. Dr. Funchain is also the co-founder of ASPIRE, and we are going to talk about that a little bit today, the Alliance for the Support and Prevention of Immune-Related Events. FYI for listeners, if you are interested in our disclosures, they are available at the transcript of this episode. Pauline, thanks so much for joining us today. Dr. Pauline Funchain: Monty, thank you for this invitation. It is always great to talk. Dr. Monty Pal: So, for the audience, Pauline and I know each other from my days as a fellow at City of Hope. She was a resident at Harbor UCLA and a stellar resident at that. It has just been amazing to sort of see your career grow and blossom and to witness all the cool things that you are doing. ASPIRE, in particular, sort of caught my eye. So again, for listeners, this is the Alliance for the Support and Prevention of Immune-Related Events. Can you tell us a little bit briefly about the genesis of that, how that came about? Dr. Pauline Funchain: So, there was a bunch of us who were really struggling, I mean, all of us have struggled with these immune-related adverse events, these irAEs. You know, they are new disease states, and even though they look like autoimmune diseases, they tend to need a whole lot more steroid than autoimmune diseases do and they do not totally present in the same way. And in fact, you know, Triple-M, or Triple-M overlap syndrome, is a completely new irAE, a new immune state that we have never had before the advent of checkpoint inhibitor. And so a Triple-M, for those of you who are not as familiar, that is the constellation of myocarditis, myositis, and myasthenia gravis, something that never occurs as a natural autoimmune disease. So we were starting to realize that there were some major differences with these irAEs and autoimmune diseases. We could not treat them the right way. We really needed to learn more about them. And a bunch of us who had interest in this said, "Look, we really need to be all in one space to talk about what we are doing," because all of our treatments were our own little homegrown brews, and we needed to really get together and understand how to treat these things, how to diagnose them, and then learn more about them. So, Dr. Alexa Meara from Ohio State, Dr. Kerry Reynolds from Mass Gen, we put together this research consortium, brought together all of our irAE friends, got our best subspecialists together in a research consortium, which is now only about a year and a half old. And we made this research consortium, the Alliance for Support of Prevention of Immune-Related Events, and we reached out to ASCO, and ASCO was so kind to grant us a [Alliance for Support and Prevention of Immune-Related adverse Events (ASPIRE)] Community of Practice. So we met for the first time as a Community of Practice at the ASCO Annual Meeting just this past June and really got an ASCO community together to really think about how to again, diagnose, prevent, treat irAEs. Dr Monty Pal: This is interesting to me. The ASCO Community of Practice phenomenon is something that I was not super familiar with. Can you explain to our listenership what is the ASCO Community of Practice model? If you have particular interests, how do you sort of get one started? Dr Pauline Funchain: Yeah, so ASCO has an entire page on their Community of Practice. There are multiple Community of Practice groups or COPs. There are ones for Supportive Oncology and Survivorship. There is Women in Oncology. There is a group for International Medical Graduates. And there is about, I think 10 or 12 now that have a physical presence at ASCO but also a virtual presence on the ASCO Community of Practice site. So, if you were interested in any one of these, and you can see them on the ASCO Communities of Practice sites, you would ask to become a member. Once granted membership, then there is a whole webpage of postings and conversations that people can have. You can get email digests of conversations that happen on the website, and then you can anchor it with in-person participation at the Annual Meeting. Dr Monty Pal: That is awesome, and I can think of so many different foci within oncology that really sort of deserve a Community of Practice. This definitely being one of them. You know, it strikes me as being so interesting. I mean, the checkpoint inhibitors have been around for a while now. I think when you and I were in training, gosh, back then, these were just a little bit of a pipe dream, right? But having said that, I would probably say that more than half of my kidney cancer practice is either on checkpoint inhibitors, and the vast majority have been on one at some point in their past, right? With that in mind, you know, we have all treated a lot of patients with these drugs. Why is it that we still struggle to manage the toxicities? And just to take that one step further, what are some of the toxicities that, perhaps through ASPIRE or through your experience, people struggle with the most? Dr Pauline Funchain: So, I think we are still struggling with these because again, they are new disease states, right? This is what we all experienced with COVID, a brand-new virus and a brand-new syndrome. We now have 20-plus of these as irAEs. And what we have realized about them is the immune activation that happens with these is so much more than what we have seen with autoimmune diseases. So for instance, if you have a Crohn's or ulcerative colitis, you will top out at 40 to 60 milligrams of prednisone if a Crohn's flare or ulcerative colitis flare happens. But for our severe IR colitises, you know, it is at least 1 mg per kg, often goes up to 2 mg per kg. We, in some cases, have done 1 gram pulses if we are worried that somebody is going to perforate. So that was sort of like the first 5 years of treating irAE, and then now in the sort of second 5 years of treating irAE, we have realized that that is a lot of immunosuppression, and we might be able to get away with less with the newer biologics that are on board. So, we are struggling to try to get the data for some of these irAEs that we knew, we have known for a while, but to try to get newer treatments that may immunosuppress less so that you may still be able to retain that tumor response. And in fact, some of the preclinical studies suggest that some of these biologics may actually synergize with the immunotherapy and actually make the immunotherapy more effective from a tumor perspective and calm down the irAE as sort of the bystander effect. So we are still trying to optimize those. Getting up trials in the space has been very difficult. That is one of the reasons for the genesis of ASPIRE because we realized we needed to band together to have a bigger voice in that realm. Then there are other things that are brand new. So we talked about Triple-M. So Triple-M, again, with Triple-M or any myocarditis or myasthenia, I mean, there is about a 50% chance of death from irAE based on the literature. I think we are getting better at recognizing this, and so at Stanford we have some data to say that if you serially follow troponin, that maybe your outcomes are better. You can potentially lower the percentage of cases that are fatal because you can catch them early. I mean, this is all preliminary data, but again, these are all things that are evolving, and we do not all have the right answer. I mean, even the serial troponin thing, I think, is pretty controversial. And in fact, at one of our quarterly Zoom meetings that we are doing in ASPIRE in December is going to sort of flush out that controversy about serial troponin measuring and what is the best thing to use? Would you use something like abatacept or would you use ruxolitinib? Which one is better? I think there is a lot of controversy still about these things. Dr Monty Pal: You have really piqued my curiosity here because you think about the cons of treating irAEs, right? And I worry exactly about what you had mentioned, right, which is, "Gosh, what is going on with this tumor in terms of immunosuppression?" But you think about some of the newer agents, you mentioned ruxolitinib, I have heard of dasatinib, for instance, in this setting. Frankly speaking, a lot of these, as you point out, are really thought of as being also anticancer drugs. So you have really got me thinking about the potential synergy between perhaps suppressing an irAE and augmenting antitumor activity, which I think is very interesting. Am I on the right track with that? Dr Pauline Funchain: I think so, but you will find that a lot of people will not even go there because they are worried about how much immunosuppression you are going to cause. I am at heart a geneticist, but I think an immunologist will happily tell you that the immune system is very complex. There are multiple pathways, and these drugs do not all target the same immune pathways. So if we understand a little bit more about the pathways we are targeting and pick apart the pathways that are really, really tumor relevant and the other pathways that are not tumor relevant, you may be able to piece together a better marriage of tumor response and irAE control. Dr Monty Pal: Kind of on this topic, and again, leaning on your background in genetics, where are we in terms of predicting these irAEs? I mean, you would think the holy grail would be picking out a snip or something of this for it, right, that could potentially identify that patient who is going to get Triple-M or, you know, at the very least a significant high-grade irAE event. Are we anywhere closer to that in 2025? Dr Pauline Funchain: There have been data published. There have been some big GWAS studies. All of the effect sizes are pretty small. So there are some prediction algorithms, but none of them are clinically useful. And I think when you look at the odds ratios, they will increase risk by maybe 20%. I think one of the things that we found in a very small series and supported anecdotally is something as easy as family history of autoimmune disease is probably more predictive at this point than any of those types of markers. I think we will get there, but we are not anywhere near where we would like to be. Things like TMB also, actually, there is some good data about higher TMB, higher risk of irAE too. Dr Monty Pal: Interesting. I see all this data coming through, IL-8 polymorphisms, etc. And I just wondered if any of that was ready for prime time. But I mean, this is a good message for the practicing clinician. Sounds like we are not quite there yet. And I could probably keep you on for another entire podcast to talk about this topic, but let us see if we can at least skim the surface. I never thought I would see the day when BiTEs and CAR-Ts were entering into my kidney cancer practice, but in fact, it is really become central to a lot of our clinical trials in RCC these days. I would be lying if I did not say that I was not struggling with the toxicities and so forth associated with these drugs. Can you give us a quick primer, maybe just good resources that people can go to for managing toxicity with BiTEs and with CAR and with some of these novel therapeutic modalities that we are using in the oncology clinics? Dr Pauline Funchain: I know there is a recently published toxicity manual for BiTEs in hematologic malignancies, I think it was in Blood. CAR-T is covered in many irAE guidelines. So ASCO guidelines actually has a CAR-T [cell therapy guideline], and I would be remiss not to point out that actually ASCO has a, I am a little biased, but a wonderful guideline on irAE that is actually being updated as we speak. We are hoping for publication next year. I find the format of that, there are many guidelines out there, actually. There is ASCO, SITC, ESMO has a guideline for irAE, but I find the formatting of the ASCO guideline to be much easier to flip through during clinic, just because of the visual format of the tables. But that is going to be updated next year. And with CAR-T, there is now multiple publications also in terms of guidelines. But what I will say about bispecifics and CAR-T, so they have very similar toxicities in terms of the cytokine release and also with the ICANS, so the neurotoxicity. But what we have been finding that is really interesting with BiTEs and CAR-T, and actually even with TIL, cytokine release is very similar to some of the IL-2 toxicities but not identical that we see with TIL treatment. But now we are starting to see overlap. So patients who have been treated with immunotherapy and then go on to get a bispecific or then go on to get TIL, so I have seen some colitises that have occurred after the fact. Some of the newer CAR-Ts without checkpoint have been causing some really interesting, probably not in a good way, but interesting biologically, colitises that are really refractory. So we are starting to see some overlap, and again, I think this field is just evolving constantly. Dr Monty Pal: Yeah, no, I almost think I need to go back to that fellowship that you and I did together 20 years ago and, you know, and see if I could repeat some coursework on CAR-T management. You know, Pauline, I could probably keep you on the horn for hours, but this has just been terrific. Thank you so much for sharing all of your insights with us today on the ASCO Daily News Podcast. Dr Pauline Funchain: Thank you for the invitation. It was wonderful to talk about this, and it was wonderful to catch up a little bit, Monty. Dr Monty Pal: Same here, same here. And thanks to our listeners too. If you value the insights you heard today on the ASCO Daily News Podcast, please rate, review, and subscribe wherever you get your podcasts. Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. Find out more about today's speakers: Dr. Monty Pal @montypal Dr. Pauline Funchain @FunchainMD Follow ASCO on social media: @ASCO on Twitter ASCO on Bluesky ASCO on Facebook ASCO on LinkedIn Disclosures: Dr. Monty Pal: Speakers' Bureau: MJH Life Sciences, IntrisiQ, Peerview Research Funding (Inst.): Exelixis, Merck, Osel, Genentech, Crispr Therapeutics, Adicet Bio, ArsenalBio, Xencor, Miyarsian Pharmaceutical Travel, Accommodations, Expenses: Crispr Therapeutics, Ipsen, Exelixis Dr. Pauline Funchain: Consulting or Advisory Role: Merck, Replimune, Sanofi/Regeneron, Immunocore, Tempus Research Funding (Inst.): Pfizer, Bristol-Myers Squibb, IDEAYA Biosciences, Linnaeus Therapeutics Travel, Accommodations, Expenses: Merck
Scott Rizzuto, Anthony Stalter, and Tim McKernan return to The Spread Zone off a 6–3 week with bold energy, spicy locks, and an actual moment of agreement. Rizz finally puts together a clean card, Stalter recovers from NFL trauma, and Tim lets the AI pick his winners. This week's slate includes Mizzou -5.5 vs. Florida, Mississippi State (yes, again), Texas Tech -7 in a playoff pipe dream, and a heated group discussion around Ohio State laying 20.5. The NFL card gets weird with Bears takes, Seahawks love, and a full fade of the Giants, plus some mild panic about Falcons futures. FanDuel Locks of the Week are in—and yes, they're feeling dangerously confident.The Spread Zone is presented by FanDuel Sportsbook.*LEGAL DISCLAIMER*We provide information about sports betting for entertainment purposes only. Please confirm gambling regulations in your state of residence. To participate in sports gaming, you must be 21 years of age or older and be physically present in a state where sports betting is legal. If you or someone you know has a sports betting or gambling problem, please call 1-800-GAMBLER or visit www.ncpgambling.org for more information and further assistance.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.
Ohio State received the No. 1 ranking as expected in the initial College Football Playoff rankings, which were released Tuesday night. Were there any surprises in the top-25? Also, is the Buckeyes' offensive line a bit banged up heading into the stretch run of the season? Head coach Ryan Day addressed that and more on Tuesday, and on today's show Dave Biddle and Patrick Murphy will give their takeaways from the press conference and what it means for OSU. That and more is coming your way on the Wednesday 5ish. To learn more about listener data and our privacy practices visit: https://www.audacyinc.com/privacy-policy Learn more about your ad choices. Visit https://podcastchoices.com/adchoices
The first College Football Playoff rankings of the 2025 season are out, putting Ohio State in a favorable place. The Buckeyes debuted in the No.1 spot in the first rankings of the new 12-team era. On this Wednesday Buckeye Talk, Stephen Means and Stefan Krajisnik break down what that means going forward. Then Andrew Gillis joins in as the trio reacts to everything Ryan Day, said as OSU prepares to face Purdue on Saturday. Learn more about your ad choices. Visit megaphone.fm/adchoices
© 2020-2025 Ivy Podcast Discovery LLC
